GSK vs Pfizer

GSK was created by the union of two massive British pharmaceutical giants. For years, the combined entity was a diversified giant, holding everything from massive pharmaceutical research labs to high-street consumer products like toothpaste and cold medicine. However, the sheer size of the organization made it slow to react to the rapid, agile innovation taking place in the biotech sector, leading to years of stagnation in its share price and R&D output.

In an attempt to redefine its strengths, GSK executed a massive, multi-billion-dollar asset swap with Novartis. GSK acquired Novartis’s vaccine business, betting that its global scale in manufacturing and distribution would make it the undisputed leader in the vaccine market. In exchange, it traded away its cancer drug business. This trade was a high-stakes, institutional bet that the future of GSK lay in preventative medicine (vaccines) rather than treating active cancer cases.

GSK finally completed the long-awaited spin-off of its massive consumer healthcare division into an independent entity called Haleon. This was a critical step in the company’s modern evolution, as it allowed GSK to stop being a "retail product company" and become a "science company." By shedding the low-growth consumer goods, GSK freed up its capital to pour exclusively into high-stakes, patent-protected drug and vaccine development.

GSK proved its vaccine-focused R&D bet was correct with the successful development and launch of Arexvy, the world’s first vaccine for RSV (Respiratory Syncytial Virus) in older adults. The successful rollout, which captured a significant, high-margin share of the market, demonstrated that GSK could once again be an elite, market-leading innovator. The success of the vaccine became a crucial pillar for the company’s new, post-consumer-spin-off financial strategy.

By mid-2026, GSK is a leaner, more focused organization. With its vaccine division serving as the engine of its growth and its R&D labs successfully producing specialized, patent-protected drugs, the firm has regained its footing as a major player in the global pharmaceutical market. Under its current leadership, GSK has successfully transitioned from a slow-moving, diversified retailer to a nimble, high-science pharmaceutical powerhouse.

Charles Pfizer and his cousin Charles Erhart emigrated from Germany to New York in the 1840s and founded a fine chemicals business in Brooklyn in 1849 with $2,500 borrowed from Pfizer's father. Their first product was santonin — an antiparasitic compound used to treat intestinal worms, which were endemic among American children in the nineteenth century. They mixed it with almond-toffee flavouring to make it palatable. The product was a commercial success, establishing Pfizer as a specialty chemicals company.

During World War II, the U.S. government selected Pfizer to scale up penicillin production for Allied forces. Pfizer's fermentation expertise — developed over decades of making citric acid — proved crucial. The company developed a deep-tank fermentation process that dramatically increased penicillin yield. By June 1944, Pfizer was producing half of all penicillin made in the United States for the D-Day invasion. The wartime relationship with the U.S. government funded Pfizer's transition from chemicals to drugs.

Pfizer's researchers were conducting clinical trials on sildenafil — a drug intended to treat angina and hypertension — when male trial participants reported an unexpected side effect and were reluctant to return unused pills at the end of the trial. Pfizer pivoted the drug's development toward erectile dysfunction and launched Viagra in 1998. It was the first oral treatment for erectile dysfunction and generated $1 billion in its first year — the fastest pharmaceutical launch in history at the time. Pfizer's share price doubled.

Pfizer partnered with German biotechnology company BioNTech in 2020 to develop an mRNA vaccine against COVID-19. The vaccine was authorised for emergency use in the United Kingdom on December 2, 2020 — less than a year after the virus was first identified. Pfizer's COVID vaccine generated $36.8 billion in revenue in 2021 alone — the highest annual revenue from a single drug in pharmaceutical history. The mRNA technology used, previously unproven at scale, opened a new era in vaccine development and eventually earned BioNTech founders Uğur Şahin and Özlem Türeci the Nobel Prize in Medicine in 2023.

Pfizer reported full-year 2025 revenues of $62.6 billion — down 2% from 2024's $63.6 billion — as COVID vaccine and antiviral revenues continued to decline. Excluding COVID products, non-COVID revenue grew 6% operationally. Pfizer had delivered $4.5 billion in cost savings through 2025, acquired oncology company Seagen for $43 billion in 2023 to build a cancer drug pipeline, and acquired Metsera in November 2025. The company that had become the world's largest pharmaceutical company on the back of a pandemic vaccine was now managing the transition back to conventional pharma economics — where blockbusters took a decade to develop instead of nine months, and rarely generated $36 billion in a single year.